ProPhase Labs Finalizing Set of Cost-saving Measures for Non-core Operations

TipRanksDec 11 08:20 ET

Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026; Targets $6M Annual Savings...

BenzingaDec 11 08:15 ET

Express News | Prophase Labs: Finalizing Cost-Saving Measures Targeting Non-Core Ops That Will Reduce Oper Expenses by at Least $6 Mln/Yr

ReutersDec 11 08:08 ET

Express News | Prophase Labs: Jay Schwartz Will Assist Co in Pursuing Strategic Alternatives Including a Potential Sale of Pharmaloz

ReutersDec 11 08:07 ET

ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting Measures

GlobeNewswireDec 11 08:00 ET

ProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call Transcript Summary

moomoo AINov 15 15:04 ET · Conference Call